Pune based Serum Institute of India stated that the COVID-19 vaccine invented by the University of Oxford would be in the market if its efficiency is proved.
This vaccine major institute in India has come in a collaboration for the research with Oxford and is one of the seven intercontinental organisation in this project.
The Chief Executive Officer of Serum Institute, Adar Poonawalla said that if the UK trial turns out to be a success, they will conduct another trial here, that too quite shortly, keeping into account it’s productiveness. Further, he also told that they would put to use one of the prevailing resources for the COVID-19 vaccine as they need more time for configuring out new provisions.
The institute is aiming to produce 4-5 million doses per month. By September- October, they would try to fulfil a target of 20-40 million doses if the trial gives desired results.
Poonawalla reported that their company would not be taken into consideration for these efforts by the investors concerning financial profits. They are investing almost Rs. 400-500 crore for the mass production of the coronavirus vaccine and he has resolved to use one of the operational equipment in the welfare of the public.
Serum Institute will also team up with the Indian Council of Medical Research (ICMR) to perform clinical experiments and is also in contact with the Department of Biotechnology (DBT).
